XT
MBRX icon

XTX Topco’s Moleculin Biotech MBRX Stock Holding History

XTX Topco’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,969
Closed -$22.4K – 2978
2025
Q2 		$22.4K Buy
2,969
+2,506
+541% +$51.4K ﹤0.01% 2147
2025
Q1 		$11.3K Buy
+463
New +$15.6K ﹤0.01% 2238
2021
Q3 		– Sell
-88
Closed -$121K – 900
2021
Q2 		$121K Buy
+88
New +$120K 0.04% 636

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
WDG
Wealth Dimensions Group Cincinnati, Ohio $558M AUM 20.63% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

XTX Topco's MBRX Position: Q3 2025 in Review

XTX Topco sold out of Moleculin Biotech (MBRX) in Q3 2025, closing a stake of 2,969 shares — an estimated $22.4K sold.

XTX Topco first reported a position in MBRX in Q2 2021 and held it in 3 quarters. The position peaked at $121K in Q2 2021. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2025.

  • XTX Topco reported no remaining Moleculin Biotech position as of Q3 2025 after selling out during the quarter.
  • XTX Topco sold 2,969 Moleculin Biotech shares in Q3 2025, an estimated $22.4K.
  • XTX Topco first reported a position in Moleculin Biotech in Q2 2021 and held it in 3 quarters.
  • XTX Topco's Moleculin Biotech position peaked at $121K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.